Eli Lilly and Company (NYSE:LLY) is Kennedy Capital Management LLC's 9th Largest Position

Kennedy Capital Management LLC lifted its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 17.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 41,351 shares of the company's stock after acquiring an additional 6,011 shares during the period. Eli Lilly and Company comprises approximately 0.7% of Kennedy Capital Management LLC's holdings, making the stock its 9th largest holding. Kennedy Capital Management LLC's holdings in Eli Lilly and Company were worth $31,923,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Highline Wealth Partners LLC raised its holdings in shares of Eli Lilly and Company by 80.0% during the fourth quarter. Highline Wealth Partners LLC now owns 45 shares of the company's stock worth $35,000 after purchasing an additional 20 shares during the period. Kovitz Investment Group Partners LLC grew its position in shares of Eli Lilly and Company by 117.1% during the 3rd quarter. Kovitz Investment Group Partners LLC now owns 46,132 shares of the company's stock valued at $41,000 after buying an additional 24,879 shares during the last quarter. FPC Investment Advisory Inc. raised its stake in Eli Lilly and Company by 358.3% during the fourth quarter. FPC Investment Advisory Inc. now owns 55 shares of the company's stock worth $45,000 after acquiring an additional 43 shares during the period. Prudent Man Investment Management Inc. bought a new position in Eli Lilly and Company in the fourth quarter worth about $48,000. Finally, Compass Financial Services Inc bought a new position in Eli Lilly and Company in the fourth quarter worth about $50,000. 82.53% of the stock is currently owned by institutional investors.

Insider Transactions at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 1,000 shares of the firm's stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total transaction of $818,240.00. Following the completion of the sale, the chief accounting officer now directly owns 5,840 shares of the company's stock, valued at $4,778,521.60. This trade represents a 14.62 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 0.13% of the company's stock.

Analysts Set New Price Targets

LLY has been the topic of a number of research reports. Leerink Partners set a $950.00 price target on Eli Lilly and Company in a research report on Friday, January 17th. Guggenheim dropped their target price on Eli Lilly and Company from $973.00 to $928.00 and set a "buy" rating on the stock in a research report on Monday. Truist Financial raised their target price on Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a "buy" rating in a research note on Monday, February 3rd. The Goldman Sachs Group upgraded shares of Eli Lilly and Company from a "neutral" rating to a "buy" rating and lowered their price target for the stock from $892.00 to $888.00 in a research report on Tuesday, April 8th. Finally, Morgan Stanley cut their price objective on shares of Eli Lilly and Company from $1,146.00 to $1,124.00 and set an "overweight" rating on the stock in a research report on Wednesday, April 9th. Two equities research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $1,012.00.

Eli Lilly and Company Price Performance

NYSE LLY traded up $15.14 on Monday, reaching $747.55. 1,488,839 shares of the stock traded hands, compared to its average volume of 3,379,060. Eli Lilly and Company has a 12 month low of $677.09 and a 12 month high of $972.53. The company has a market cap of $708.80 billion, a price-to-earnings ratio of 63.84, a P/E/G ratio of 1.40 and a beta of 0.51. The firm's fifty day simple moving average is $837.05 and its 200 day simple moving average is $822.87. The company has a quick ratio of 0.97, a current ratio of 1.15 and a debt-to-equity ratio of 2.00.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its earnings results on Thursday, February 6th. The company reported $5.32 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. As a group, research analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.